FDA announce voluntary market withdrawal of Octagam immune globulin intravenous liquid preparation

0

…Octapharma has determined, through consultation with the public health authorities at FDA, the most prudent course of action is to suspend further administration of octagam 10%…” FDA (2017).

FDA report “Octapharma USA Inc. is initiating a voluntary market withdrawal of octagam 10% 10% Liquid Preparation] that is labeled with lot numbers K724B8541 & K725A8541. Although there have been no reports of serious injury at this time, Octapharma has determined, through consultation with the public health authorities at FDA, the most prudent course of action is to suspend further administration of octagam 10% from these particular production lots.”

Full Alert

Thank you to our partners for supporting IVTEAM

Share.

Comments are closed.